SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+17.19%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$189M
AUM Growth
+$189M
(+15%)
Cap. Flow
+$12.7M
Cap. Flow
% of AUM
6.75%
Top 10 Holdings %
Top 10 Hldgs %
41.3%
Holding
79
New
19
Increased
18
Reduced
20
Closed
16
Top Buys
| 1 |
Mersana Therapeutics
MRSN
|
$7.32M |
| 2 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$7.32M |
| 3 |
Natera
NTRA
|
$7.3M |
| 4 |
Lantheus
LNTH
|
$6.46M |
| 5 |
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
|
$5.73M |
Top Sells
| 1 |
Zymeworks
ZYME
|
$15.4M |
| 2 |
Prothena Corp
PRTA
|
$7.06M |
| 3 |
AstraZeneca
AZN
|
$6.96M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
$3.63M |
| 5 |
Spyre Therapeutics
SYRE
|
$3.42M |
Sector Composition
| 1 | Healthcare | 94.21% |
| 2 | Real Estate | 0.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ESSA Pharma
EPIX
$11.4M
| $12.6M | 6.68% | 1,826,980 -255,205 | -12% | -$1.76M |
|
|
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.51M | 5.04% | 1,685,879 +59,178 | +4% | +$334K |
|
3
OraSure Technologies
OSUR
$242M
| $7.61M | 4.03% | 625,109 +401,909 | +180% | +$4.89M |
|
|
4
Mersana Therapeutics
MRSN
$36.5M
| $7.32M | 3.88% | +393,041 | New | +$7.32M |
|
|
INBX
5
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $7.32M | 3.88% | +406,500 | New | +$7.32M |
|
|
6
Natera
NTRA
$23.1B
| $7.3M | 3.87% | +101,089 | New | +$7.3M |
|
7
QuidelOrtho
QDEL
$1.95B
| $6.75M | 3.58% | 30,751 -149 | -0.5% | -$32.7K |
|
8
Vericel Corp
VCEL
$1.83B
| $6.54M | 3.47% | 353,006 +114,474 | +48% | +$2.12M |
|
|
IMMU
9
DELISTED
Immunomedics Inc
IMMU
| $6.49M | 3.44% | 76,268 -42,732 | -36% | -$3.63M |
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $6.48M | 3.44% | 46,166 +11,666 | +34% | +$1.64M |
|
|
11
Lantheus
LNTH
$3.73B
| $6.46M | 3.42% | +509,544 | New | +$6.46M |
|
12
NovoCure
NVCR
$1.38B
| $5.83M | 3.09% | 52,377 -4,020 | -7% | -$447K |
|
|
TCRR
13
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $5.73M | 3.04% | +282,041 | New | +$5.73M |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $5.54M | 2.94% | 500,264 +249,367 | +99% | +$2.76M |
|
|
CMPS
15
Compass Pathways
CMPS
$424M
| $5.48M | 2.9% | +156,982 | New | +$5.48M |
|
16
iRadimed
IRMD
$921M
| $4.25M | 2.25% | 198,739 -13,697 | -6% | -$293K |
|
|
17
Zymeworks
ZYME
$1.12B
| $4.16M | 2.2% | 89,233 -331,603 | -79% | -$15.4M |
|
|
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.06M | 2.15% | 52,227 +22,627 | +76% | +$1.76M |
|
19
Cardiff Oncology
CRDF
$140M
| $4M | 2.12% | +281,819 | New | +$4M |
|
|
EIGR
20
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.85M | 2.04% | 472,558 -147,708 | -24% | -$1.2M |
|
21
Adverum Biotechnologies
ADVM
$64.6M
| $3.75M | 1.99% | 364,349 +145,626 | +67% | +$1.5M |
|
|
ALXN
22
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $3.44M | 1.82% | 30,077 -20,712 | -41% | -$2.37M |
|
23
Biogen
BIIB
$19.4B
| $3.28M | 1.74% | 11,556 +9,256 | +402% | +$2.63M |
|
|
OSH
24
DELISTED
Oak Street Health, Inc.
OSH
| $3.15M | 1.67% | +58,892 | New | +$3.15M |
|
25
DexCom
DXCM
$29.5B
| $3.13M | 1.66% | 7,583 -1,967 | -21% | -$811K |
|